The case was seen as a test of a more aggressive policy by the agency.
Related Posts
AbbVie Solidifies Immunology Dominance with $10.9 Billion Acquisition of Apogee Therapeutics
AbbVie (NYSE: ABBV) today announced the successful completion of its acquisition of Apogee Therapeutics (NASDAQ: APGE), an all-cash transaction valued at approximately $10.9 billion. Under the terms...
Lilly Adds to Immune Drug Pipeline with $2.9B Merida Buyout
In a strategic maneuver to solidify its presence beyond the metabolic health sector, Eli Lilly and Company (NYSE: LLY) announced on August 31, 2026, a definitive agreement to acquire Merida...
Curium Strikes $8 Billion Mega-Deal for Lantheus to Forge Global Radiopharmaceutical Powerhouse
In a definitive move to dominate the rapidly expanding nuclear medicine landscape, Curium US Holdings has entered into a definitive agreement to acquire Lantheus Holdings, Inc. (NASDAQ: LNTH) for a...
AstraZeneca Shares Tumble on Reports of $400 Billion Bristol Myers Squibb Merger Talks
AstraZeneca PLC (LON: AZN) shares fell as much as 7% in London trading on Monday, August 3, 2026, following reports that the British pharmaceutical giant has held preliminary discussions regarding a...